Cargando…

Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Shashank, Pandey, Abhay Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955633/
https://www.ncbi.nlm.nih.gov/pubmed/36826066
http://dx.doi.org/10.3390/curroncol30020105
_version_ 1784894394787168256
author Kumar, Shashank
Pandey, Abhay Kumar
author_facet Kumar, Shashank
Pandey, Abhay Kumar
author_sort Kumar, Shashank
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other locoregional therapy to improve the outcomes of advanced HCC is restricted and far from ideal. The registered trials did not identify a treatment that prolonged recurrence-free survival, the primary outcome of the majority of research. Several investigator-initiated trials have demonstrated that various treatments extend patients’ recurrence-free or overall survival after curative therapies. In the past decade, targeted therapy has made significant strides in the treatment of advanced HCC. These targeted medicines produce antitumour effects via specific signals, such as anti-angiogenesis or advancement of the cell cycle. As a typical systemic treatment option, it significantly improves the prognosis of this fatal disease. In addition, the combination of targeted therapy with an immune checkpoint inhibitor is redefining the paradigm of advanced HCC treatment. In this review, we focused on the role of approved targeted medicines and potential therapeutic targets in unresectable HCC.
format Online
Article
Text
id pubmed-9955633
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99556332023-02-25 Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma Kumar, Shashank Pandey, Abhay Kumar Curr Oncol Review Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other locoregional therapy to improve the outcomes of advanced HCC is restricted and far from ideal. The registered trials did not identify a treatment that prolonged recurrence-free survival, the primary outcome of the majority of research. Several investigator-initiated trials have demonstrated that various treatments extend patients’ recurrence-free or overall survival after curative therapies. In the past decade, targeted therapy has made significant strides in the treatment of advanced HCC. These targeted medicines produce antitumour effects via specific signals, such as anti-angiogenesis or advancement of the cell cycle. As a typical systemic treatment option, it significantly improves the prognosis of this fatal disease. In addition, the combination of targeted therapy with an immune checkpoint inhibitor is redefining the paradigm of advanced HCC treatment. In this review, we focused on the role of approved targeted medicines and potential therapeutic targets in unresectable HCC. MDPI 2023-01-18 /pmc/articles/PMC9955633/ /pubmed/36826066 http://dx.doi.org/10.3390/curroncol30020105 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kumar, Shashank
Pandey, Abhay Kumar
Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
title Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
title_full Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
title_fullStr Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
title_full_unstemmed Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
title_short Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
title_sort potential molecular targeted therapy for unresectable hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955633/
https://www.ncbi.nlm.nih.gov/pubmed/36826066
http://dx.doi.org/10.3390/curroncol30020105
work_keys_str_mv AT kumarshashank potentialmoleculartargetedtherapyforunresectablehepatocellularcarcinoma
AT pandeyabhaykumar potentialmoleculartargetedtherapyforunresectablehepatocellularcarcinoma